- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01016678
Treximet Early Intervention Adolescent Migraine (TEAM)
Early Intervention, Randomized, Mulitcenter, Placebo-Controlled, 4-Period Crossover, Multi-Attack Study to Evaluate Efficacy & Safety of ComboProduct Containing Sumatriptan and Naproxen Sodium for Acute Treatment of Migraine in Adolescents
Study Overview
Detailed Description
There are two primary treatment comparisons for this study: 1) the percentage of subjects' pain free at 2 hours after treatment with TREXIMET versus placebo across attacks, and 2) the percentage of subjects who are sustained pain free at 24 hours after treatment with TREXIMET versus placebo across attacks.
The following alternative hypothesis will be tested to see if there is a difference in the proportion of subjects who are pain free at 2 hours with TREXIMET versus placebo at all attacks, OR there is a difference in the proportion of subjects who are sustained pain free at 24 hours with TREXIMET versus placebo at all attacks.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Florida
-
West Palm Beach, Florida, United States, 33407
- Premiere Research Institute
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Andrew Hershey
-
-
Texas
-
Dallas, Texas, United States, 75230
- Steve L. Linder
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Don W. Lewis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects between the ages of 12-17.
- Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1). A history of at least 1 but no more than 8 attacks per month on average over the past 6 months prior to screening visit. Attacks should be moderate to severe and last for at least 3 hours.
- Subject is able to distinguish migraine from other headaches and can determine when a mild headache will become a moderate/severe migraine.
- Female subjects are eligible for participation provided they are of non-child bearing potential or if started menses; they are on a stable regimen of approved contraception.
- Subject and subject's parent or legal guardian are able to read and write English.
- Subject is able to read, comprehend, and complete subject diaries.
- Subjects' parent or legal guardian is willing and able to provide Informed Consent prior to subject entry into the study.
- Subject is willing and able to provide Informed Assent prior to entry into the study.
Exclusion Criteria
Subjects meeting any of the following criteria must not be enrolled in the study:
- Subject is < 74 pounds (33.3kg) and no greater than 260lbs (117.9kg)
- Subject has greater than or equal to 15 headache days per month in total.
- Subject has secondary headaches i.e. complex migraine, hemiplegic, or basilar.
- Subject, in investigators opinion is likely to have unrecognized cardiovascular or cerebrovascular disease.
- Subject has uncontrolled hypertension at screening or is taking an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker.
- Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in the study.
- Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with the above.
- Subject has a evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an anti-epileptic drug for seizure control within 5 years prior to screening.
- Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study.
- Subject has a hypersensitivity, allergy, intolerance, or contraindication to the use any triptan, NSAID, or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps or asthma.
- Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized for at least two months for either chronic or intermittent migraine prophylaxis or other co-morbid condition.
- Subject has taken or plans to take a monoamine oxidase inhibitor (MAOI) including herbal preparations containing St. Johns Wort (Hypericum perforatum), anytime within the two weeks prior to screening and two weeks past exit of study.
- Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent.
- Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease.
- Subject is pregnant, actively trying to become pregnant, or breast feeding or Subject is not willing to have pregnancy test(s).
- Subject has evidence of illicit drug or alcohol abuse within the last year or any concurrent psychiatric condition which, in the investigator's opinion, will likely interfere with study conduct and participation in the trial.
- Subject has participated in any investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Active, Active, Active, Placebo
One fifth of the 105 subjects will be randomized to this arm and treat their four migraines in this order.
First three will be treated with Active Treximet and the last or 4th migraine will be treated with Placebo.
|
85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache.
The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
Other Names:
Dummy pill comparator
Other Names:
|
Other: Active, Active, Placebo, Active
This is another of the five treatment arms.
One fifth of the 105 subjects will be randomized to this group and will treat the first two migraines with Active drug, Treximet, and then the third migraine with placebo and the last (4th) migraine with Treximet.
|
85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache.
The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
Other Names:
Dummy pill comparator
Other Names:
|
Other: Active, Placebo, Active, Active
Approximately one fifth of the 105 subjects will be randomized to this group and treat their first migraine with Active Treximet and the second migraines with Placebo.
The final two migraines treated will be with Active study drug.
|
85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache.
The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
Other Names:
Dummy pill comparator
Other Names:
|
Other: Placebo, Active, Active, Active
One fifth of the 105 subjects will be randomized to this treatment arm, where they will treat the first headache with placebo and the remaining three migraines will be treated with Active treximet.
|
85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache.
The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
Other Names:
Dummy pill comparator
Other Names:
|
Other: Active, Active, Active, Active
One fifth of the subject will treat all their migraines with Active Treximet.
|
85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache.
The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With 2-hour Pain Free Active Study Drug
Time Frame: 3 years
|
All data was collected and measured from self-reported patient diaries
|
3 years
|
Percentage of Migraine Attacks With Sustained Pain Free Response From 2 to 24 Hours Post-Dose
Time Frame: 3 years
|
All data was collected and measured from self-reported patient diaries
|
3 years
|
Percentage of Migraine Attacks With Pain Free Response at 2 Hours Post-Dose Following Early Intervention
Time Frame: 3 years
|
All data was collected and measured from self-reported patient diaries
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To Evaluate the Consistency of Response Across Four Migraine Attacks at 1, 2, 4, and 24 Hours After Treatment. Frequency of Rescue Medications Needed and the Consistency of Other Symptom Relief i.e. Nausea, Vomiting, Photophobia, and Phonophobia.
Time Frame: 3 years
|
Collected from patient reported paper diaries
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Paul K Winner, DO, Premiere Research Institute
- Principal Investigator: Andrew Hershey, MD, Cincinnati Childrens Hospital
- Principal Investigator: Steve L Linder, MD, Dallas Pediatric Neurology Associates
- Principal Investigator: Donald W Lewis, MD, Childrens Hospital of the King's Daughters
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Gout Suppressants
- Naproxen
Other Study ID Numbers
- TEAM2009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Treximet
-
Gary E. Ruoff, M.D.GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedMigraine Disorders | Migraine, AcuteUnited States
-
Johns Hopkins UniversityThe Cleveland Clinic; University of Toledo Health Science CampusCompleted
-
Stephen H. Landy, M.D.GlaxoSmithKlineCompletedMigraineUnited States
-
Dent Neurologic InstituteUnknown
-
GlaxoSmithKlineCompletedMigraine DisordersUnited States
-
Cady, Roger, M.D.GlaxoSmithKlineTerminatedPost-Traumatic HeadacheUnited States
-
GlaxoSmithKlineCompletedMigraine Disorders
-
Cady, Roger, M.D.GlaxoSmithKlineCompleted
-
Cady, Roger, M.D.GlaxoSmithKlineCompleted